 GlaxoSmithKline plc NYSE: GSK said that its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology Inc NASDAQ: VIR is effective against all mutations of the new Omicron coronavirus variant, citing new data from preclinical studies. The data shows that the companies treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein. 